Minerva Endocrinol (2020) 4:12737
Clinical Evidence HIV patients: 26-week trials show 20% reduction in abdominal fat Metabolic syndrome patients: Improvements in triglycerides, liver fat, and insulin sensitivity Ideal Candidates for Tesamorelin People with visceral obesity Patients with metabolic syndrome or insulin resistance Individuals able to commit to daily injections and lab monitoring Ipamorelin: Gentle Growth Hormone Booster Ipamorelin is a selective ghrelin receptor agonist that stimulates GH without significantly affecting cortisol, prolactin, or ACTH
This suggests that young, female, lower-weight patients may be more susceptible to IGE from GLP-1RA therapy
Want to know which whitening treatment suits your skin
In fact, you can find the perfect treatment from your phone or computer
The approach with retatrutide will likely be similar, but we won't have official guidance until it's approved